Investment Rating - The industry rating is "Outperform the Market" [7] Core Insights - The report highlights that the National Health Commission has revised the management measures for the National Essential Medicines List, indicating that a new list will be released soon, which is expected to boost the volume of newly included products [4][18]. - The report suggests that the Chinese medicine sector is currently undervalued and underrepresented, with potential for a turning point due to policy catalysts, falling raw material prices, and inventory clearance [4][20]. - The report emphasizes that the pharmaceutical sector has been under pressure, with the CITIC Pharmaceutical Index down 2.9% for the week and 2.7% year-to-date, underperforming the CSI 300 Index [3][26]. Summary by Sections Market Review - The CITIC Pharmaceutical Index fell by 2.9% from March 16 to March 20, 2026, underperforming the CSI 300 Index by 0.8 percentage points, ranking 10th among CITIC's primary industry classifications [3][26]. - The top five performing stocks during this period were *ST Jingfeng (+27.7%), Sanofi (+23.1%), Jieda Biological (+15.6%), Jiuan Medical (+12.7%), and Xinlitai (+10.9%) [3][44]. Policy and Market Opportunities - The upcoming revision of the essential medicines list is expected to clarify the implementation of the "986" policy, which mandates that a certain percentage of essential medicines be stocked in various healthcare institutions [20][24]. - The report recommends focusing on leading state-owned enterprises and brand-name Chinese medicine companies, as well as potential opportunities in the essential medicines list [4][20]. Investment Strategy - The report outlines a strategy for 2026, focusing on three main areas: innovative drugs, medical devices, and companies benefiting from domestic demand [5][4]. - Suggested stocks for investment include Kangfang Biotech, Innovent Biologics, WuXi AppTec, and Sanli Pharmaceutical [5][14]. Performance Metrics - The overall valuation of the pharmaceutical sector as of March 20, 2026, is 27.91, with a relative valuation premium of 2.93% compared to the broader A-share market [34][41]. - The total trading volume for the pharmaceutical sector during the week was 417.38 billion yuan, accounting for 3.8% of the total A-share trading volume [41][44].